Lazard Asset Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Lazard Asset Management’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-9,000	Closed	-$161K	–	1175
2017 Q4	$161K	Hold	9,000	–	–	﹤0.01%	893
2017 Q3	$106K	Buy	9,000 +1,000	+13%	+$11.2K	﹤0.01%	823
2017 Q2	$84K	Buy	8,000 +1,000	+14%	+$10.2K	﹤0.01%	823
2017 Q1	$77K	Hold	7,000	–	–	﹤0.01%	855
2016 Q4	$94K	Hold	7,000	–	–	﹤0.01%	845
2016 Q3	$86K	Hold	7,000	–	–	﹤0.01%	839
2016 Q2	$76K	Buy	+7,000	New	+$78.4K	﹤0.01%	876

Other funds holding SCMP

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Lazard Asset Management's SCMP Position: Q1 2018 in Review

Lazard Asset Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 9,000 shares — an estimated $161K sold.

Lazard Asset Management first reported a position in SCMP in Q2 2016 and held it in 7 quarters. The position peaked at $161K in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

Lazard Asset Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Lazard Asset Management sold 9,000 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $161K.
Lazard Asset Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2016 and held it in 7 quarters.
Lazard Asset Management's Sucampo Pharmaceuticals, Inc. position peaked at $161K in Q4 2017.
3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Lazard Asset Management's 13F filing for Q1 2018, filed 14 May 2018.